{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:31:49Z","timestamp":1791498709138,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T00:00:00Z","timestamp":1528848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.clml.2018.05.022","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T05:16:30Z","timestamp":1528262190000},"page":"e327-e331","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma"],"prefix":"10.1016","volume":"18","author":[{"given":"John M.","family":"Burke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Shustov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Essell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipti","family":"Patel-Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Sharman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2018.05.022_bib1","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/leu.2008.346","article-title":"Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells","volume":"23","author":"Gobessi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.022_bib2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.beha.2007.04.001","article-title":"The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia","volume":"20","author":"Kipps","year":"2007","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2018.05.022_bib3","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1182\/blood-2003-12-4312","article-title":"Chronic lymphocytic leukemia: revelations from the B-cell receptor","volume":"103","author":"Stevenson","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1146\/annurev.immunol.21.120601.141018","article-title":"B\u00a0cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor","volume":"21","author":"Chiorazzi","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.clml.2018.05.022_bib5","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2009-07-233692","article-title":"Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia","volume":"115","author":"Buchner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib6","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2009-03-212837","article-title":"B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406","volume":"114","author":"Quiroga","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2009-08-236471","article-title":"Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia","volume":"115","author":"Friedberg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/asheducation-2013.1.553","article-title":"Targeting B-cell receptor signaling: changing the paradigm","volume":"1","author":"Fowler","year":"2013","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2018.05.022_bib9","doi-asserted-by":"crossref","unstructured":"Ramanathan S, Di Paolo JA, Doan T, et\u00a0al. Single and multiple dose-ranging evaluation of safety, pharmacokinetics, and pharmacodynamics of GS-9973, a novel pSYK inhibitor. Poster presented at American Association for Cancer Research 104th Annual Meeting, April 6-10, 2013, Washington, DC.","DOI":"10.1158\/1538-7445.AM2013-32"},{"key":"10.1016\/j.clml.2018.05.022_bib10","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.1021\/jm500228a","article-title":"Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase","volume":"57","author":"Currie","year":"2014","journal-title":"J\u00a0Med Chem"},{"key":"10.1016\/j.clml.2018.05.022_bib11","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1182\/blood-2014-08-595934","article-title":"An open-label phase 2 trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in chronic lymphocytic leukemia","volume":"125","author":"Sharman","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2018.05.022_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/2040620716636542","article-title":"Targeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinib","volume":"7","author":"Sharman","year":"2016","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2018.05.022_bib14","doi-asserted-by":"crossref","first-page":"6342","DOI":"10.1182\/blood-2011-02-333773","article-title":"SYK inhibition and response prediction in diffuse large B-cell lymphoma","volume":"118","author":"Cheng","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1182\/blood.V124.21.505.505","article-title":"Combination of ibrutinib and BCL-2 or SYK inhibitors in ibrutinib resistant ABC-subtype of diffuse large B-cell lymphoma","volume":"124","author":"Kuo","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib16","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.ccr.2013.05.002","article-title":"SYK inhibition modulates distinct PI3K\/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas","volume":"23","author":"Chen","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2018.05.022_bib17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hon.981","article-title":"In\u00a0vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas","volume":"29","author":"Rinaldi","year":"2011","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2018.05.022_bib18","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1182\/blood-2008-05-158618","article-title":"Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target","volume":"113","author":"Young","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib19","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1158\/1078-0432.CCR-14-1134","article-title":"Inhibition of NANOG\/NANOGP8 downregulates MCL-1 in colorectal cancer cells and enhances the therapeutic efficacy of BH3 mimetics","volume":"20","author":"Mattoo","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.05.022_bib20","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2018.05.022_bib21","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/leu.2015.179","article-title":"Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients","volume":"30","author":"Jilg","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2018.05.022_bib22","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1182\/blood-2015-10-675009","article-title":"BCR signaling inhibitors differ in their ability to overcome Mcl-1-mediated resistance of CLL B cells to ABT-199","volume":"127","author":"Bojarczuk","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib23","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1182\/blood-2015-11-682906","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Aguilar-Hernandez","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2018.05.022_bib24","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1158\/1078-0432.CCR-16-1662","article-title":"The dual Syk\/JAK inhibitor cerdulatinib antagonizes B-cell receptor and microenvironmental signaling in chronic lymphocytic leukemia","volume":"23","author":"Blunt","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2018.05.022_bib25","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1182\/blood.V126.23.5123.5123","article-title":"The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model","volume":"126","author":"Axelrod","year":"2015","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302386?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018302386?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:30:40Z","timestamp":1761870640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018302386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["S2152265018302386"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2018.05.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}